Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study.

Trial Profile

Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery restenosis; Coronary disorders; Stent thrombosis
  • Focus Therapeutic Use
  • Acronyms ZEUS
  • Most Recent Events

    • 01 Nov 2013 Study design published in American Heart Journal.
    • 09 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Additional trial locations (Hungary, Switzerland) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top